The FDA has issued a statement about the availability of immunoglobulin products, which many myositis patients depend upon for treatment of their disease.
The statement says, in part: ” In the setting of the increased demand for Ig, other factors that ordinarily might not impact availability may have a greater effect. These could include uneven product distribution across different localities, logistics of contractual obligations, production delays, and other factors.”
The statement offers advice to care providers and lists all licensed sources for Ig products. You can read the entire statement here.
See also TMA’s statement IG products in short supply.